Advertisement

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 600x60px
Document › Details

Kiadis Pharma N.V.. (9/5/17). "Press Release: Kiadis Pharma Appoints Karl Hård as Head of Investor Relations and Communications". Amsterdam-Duivendrecht.

Organisation Organisation AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
Product Product public relations / investor relations (services)
Person Person Hård, Karl (Kiadis 201709– Head IR + Communications before Redx Pharma 201610– Head of IR + CorpComm before AstraZeneca)
     


Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders, today announces the appointment of Dr. Karl Hård as Head of Investor Relations and Communications.

Karl has spent almost 20 years at AstraZeneca PLC based in Sweden and the UK. Over a period of 10 years, he held senior roles within Investor Relations, latterly as head of IR. Prior to that, he worked as Global Program Director, establishing new external collaborations, and as Director in Biological Chemistry, leading research into novel pharmacological targets. Karl’s scientific experience covers numerous fields, including oncology and immunology, as evidenced by over 40 published scientific articles in peer-reviewed international journals.

In the 1990s Karl was Assistant Professor in Chemistry at Leiden University, The Netherlands, and he holds a PhD in Chemistry from Utrecht University, The Netherlands.

Arthur Lahr, CEO of Kiadis Pharma, commented: “I am very pleased to welcome Karl Hård to Kiadis Pharma as Head of Investor Relations and Communications. Karl is a highly regarded IR professional with excellent relationships within the international investment community. His experience will be invaluable as we continue to further prepare the Company for the potential European commercial launch in 2019 of our wholly-owned product ATIR101™.”

Karl Hård added: “It is an exciting time to be working within the cellular immunotherapy field and I am particularly enthused by the potential of ATIR101™ to help patients. I am looking forward to working with the highly experienced management team to further increase visibility of the unique opportunity that Kiadis Pharma offers to investors.’’


About Kiadis Pharma

Kiadis Pharma is focused on cell-based immunotherapy products, as an adjunctive to a haploidentical hematopoietic stem cell transplantation (HSCT), for the treatment of blood cancers and inherited blood disorders. The Company’s product candidates have the potential to make allogeneic HSCT safer and more effective for patients.

Based on the positive results from the single dose Phase II trial with lead product ATIR101™ in patients with blood cancer, the Company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in April 2017, for approval of ATIR101™ across the European Union as an adjunctive treatment in HSCT for malignant disease. In addition, Kiadis Pharma has received regulatory approval in various countries to start dosing patients in a Phase III trial with ATIR101™ that will be performed across Europe and North America. ATIR101™ has been granted Orphan Drug Designations both in the US and Europe.

The Company’s second product candidate, ATIR201™, will address beta thalassemia, an inherited blood disorder.

Kiadis Pharma was granted an Advanced Therapy Medicinal Product (ATMP) certificate for manufacturing quality and non-clinical data by the EMA.

The Company’s shares are listed on Euronext Amsterdam and Euronext Brussels.

Company website: www.kiadis.com


For more information, please contact:

Kiadis Pharma:
Karl Hård
Head of IR & Communications
Tel. +31 611 096 298
k.hard@kiadis.com

Consilium Strategic Communications:
Mary-Jane Elliott, Philippa Gardner, Lindsey Neville, Hendrik Thys
Tel: +44 203 709 5708
kiadis@consilium-comms.co


Forward Looking Statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

   
Record changed: 2017-09-06

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 600x60px




» top

Advertisements

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 41 Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 22 Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px